Article: Diabetes Antibody Standardization Program: First evaluation of assays for autoantibodies to IA-2β

Objective: Autoantibodies to IA-2β (IA-2βA) are important risk markers of type 1 diabetes. We report the first Diabetes Antibody Standardization Program (DASP) evaluation of IA-2βA assays.

Research Design And Methods: Thirteen laboratories from nine countries received coded sera from 50 patients with newly diagnosed type 1 diabetes and 100 healthy blood donors. IA-2βA results were analyzed using receiver operating characteristic (ROC) curves. Concordance of antibody levels was compared using counts per minute (cpm), local and standard curve-derived common units.

Results: Median laboratory-assigned sensitivity was 47% (interquartile range [IQR] 45-51), specificity 98% (IQR 95-99), adjusted sensitivity at 95% specificity 50% (IQR 49-53), and area under the ROC curve 0.70 (IQR 0.69-0.73). Use of common IA-2βA units improved concordance between assays compared with local units and cpm (P < 0.0001).

Conclusions: IA-2βA assays in multiple laboratories worldwide achieved good concordance and high specificity for type 1 diabetes. IA-2βA are suitable for inclusion in autoantibody testing for risk assessment in prediabetes.

Citing Articles

Multi-omics Investigations in Endocrine Systems and Their Clinical Implications.

Peliciari-Garcia R, de Barros C, Secio-Silva A, de Barros Peruchetti D, Romano R, Bargi-Souza P Adv Exp Med Biol. 2024; 1443:187-209.

PMID: 38409422 DOI: 10.1007/978-3-031-50624-6_10.

Immunological markers in type 1 diabetes mellitus in Thi-Qar province, southern Iraq.

Hamadi G J Med Life. 2022; 15(10):1234-1239.

PMID: 36420297 PMC: 9675295. DOI: 10.25122/jml-2021-0387.

Persistent C-peptide secretion in Type 1 diabetes and its relationship to the genetic architecture of diabetes.

McKeigue P, Spiliopoulou A, McGurnaghan S, Colombo M, Blackbourn L, McDonald T BMC Med. 2019; 17(1):165.

PMID: 31438962 PMC: 6706940. DOI: 10.1186/s12916-019-1392-8.

Islet autoantibody positivity in overweight and obese adults with type 2 diabetes.

Pilla S, Balasubramanyam A, Knowler W, Lazo M, Nathan D, Pi-Sunyer X Autoimmunity. 2019; 51(8):408-416.

PMID: 30661481 PMC: 6362362. DOI: 10.1080/08916934.2018.1547711.

Immune Mechanisms and Pathways Targeted in Type 1 Diabetes.

Jacobsen L, Newby B, Perry D, Posgai A, Haller M, Brusko T Curr Diab Rep. 2018; 18(10):90.

PMID: 30168021 PMC: 8053389. DOI: 10.1007/s11892-018-1066-5.

References

1.

Bonifacio E, Lampasona V, Bingley P . IA-2 (islet cell antigen 512) is the primary target of humoral autoimmunity against type 1 diabetes-associated tyrosine phosphatase autoantigens. J Immunol. 1998; 161(5):2648-54. View

2.

Achenbach P, Schlosser M, Williams A, Yu L, Mueller P, Bingley P . Combined testing of antibody titer and affinity improves insulin autoantibody measurement: Diabetes Antibody Standardization Program. Clin Immunol. 2006; 122(1):85-90. DOI: 10.1016/j.clim.2006.09.004. View

3.

Christie M, Genovese S, Cassidy D, Bosi E, Brown T, Lai M . Antibodies to islet 37k antigen, but not to glutamate decarboxylase, discriminate rapid progression to IDDM in endocrine autoimmunity. Diabetes. 1994; 43(10):1254-9. DOI: 10.2337/diab.43.10.1254. View

4.

Decochez K, De Leeuw I, Keymeulen B, Mathieu C, Rottiers R, Weets I . IA-2 autoantibodies predict impending type I diabetes in siblings of patients. Diabetologia. 2002; 45(12):1658-66. DOI: 10.1007/s00125-002-0949-8. View

5.

De Grijse J, Asanghanwa M, Nouthe B, Albrecher N, Goubert P, Vermeulen I . Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2beta) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease:.... Diabetologia. 2010; 53(3):517-24. DOI: 10.1007/s00125-009-1618-y. View

6.

Achenbach P, Warncke K, Reiter J, Naserke H, Williams A, Bingley P . Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes. 2004; 53(2):384-92. DOI: 10.2337/diabetes.53.2.384. View

7.

Schlosser M, Mueller P, Torn C, Bonifacio E, Bingley P . Diabetes Antibody Standardization Program: evaluation of assays for insulin autoantibodies. Diabetologia. 2010; 53(12):2611-20. DOI: 10.1007/s00125-010-1915-5. View

8.

Bingley P, Bonifacio E, Mueller P . Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes. 2003; 52(5):1128-36. DOI: 10.2337/diabetes.52.5.1128. View

9.

Achenbach P, Bonifacio E, Williams A, Ziegler A, Gale E, Bingley P . Autoantibodies to IA-2beta improve diabetes risk assessment in high-risk relatives. Diabetologia. 2008; 51(3):488-92. DOI: 10.1007/s00125-007-0912-9. View

10.

Hoppu S, Harkonen T, Ronkainen M, Akerblom H, Knip M . IA-2 antibody epitopes and isotypes during the prediabetic process in siblings of children with type 1 diabetes. J Autoimmun. 2004; 23(4):361-70. DOI: 10.1016/j.jaut.2004.09.005. View

11.

Torn C, Mueller P, Schlosser M, Bonifacio E, Bingley P . Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia. 2008; 51(5):846-52. DOI: 10.1007/s00125-008-0967-2. View

Diabetes Antibody Standardization Program: First Evaluation of Assays for Autoantibodies to IA-2β